Compare Mattel Inc (MAT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Medpace Holdings Inc — how do they compare? Mattel Inc trades at $17.07 (market cap $4.74B), while Medpace Holdings Inc trades at $615.1 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 3.5× Mattel Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Medpace Holdings Inc for 14 Days on average.
| MAT | MEDP | |
|---|---|---|
Market Cap | $4.74B | $16.82B |
Volume | 11,809,722 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $630.19 |
52-Week Low | $12.66 | $393.42 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $6.96B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% on the day, with a bullish technical signal and strong profitability metrics including a 20.5% ROE and 7.78% net margin. Recent news highlights takeover interest from Authentic Brands Group and a CEO transition to Roger Lynch. Cash flow turned negative in 2025 at -$145M, but revenue remains stable around $5.3B.
The stock presents a mixed outlook: analyst consensus is a Buy with a $15.00 price target, but recent earnings misses and negative cash flow pose risks. Upside is supported by takeover speculation and solid brand portfolio, while execution under new leadership and Barbie sales trends are key watchpoints.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
